Less is more when it comes to E2 for hot flushes

Article

As little as 0.014 mg/d transdermal 17B-estradiol (E2) is enough to significantly reduce the number of moderate and severe hot flushes in postmenopausal women.

As little as 0.014 mg/d trans dermal 17ß-estradiol (E2) is enough to significantly reduce the number of moderate and severe hot flushes in postmenopausal women, according to the results of a randomized, double-blind, placebo-controlled multicenter trial.

Healthy postmenopausal women aged 40 years and older who experienced at least 50 hot flushes per week applied transdermal patches containing either a combination of 0.023 mg/d 17ß–estradiol and 0.0075 mg/d levonorgestrel, 0.014 mg/d E2 alone, or placebo for 12 weeks.

Compared with placebo, the average number of moderate and severe hot flushes per week was reduced by 51.8 episodes (P<0.001) in the combination group and by 38.46 (P<0.001) in the microdose E2 group. Almost half (41.3%) of the women receiving the microdose of E2 had a 75% or greater reduction from baseline in hot flush frequency (P=0.003) versus 24.2% of the women receiving placebo. And relief was provided quickly: mean reduction in frequency of hot flushes was 50% by week 2, 70% by week 4, 90% by week 8, and 95% by week 12, with side effects comparable to those experienced by the women receiving placebo.

Bachmann GA, Schaefers M, Uddin A, et al. Lowest effective transdermal 17ß-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;110:771-779.

Commentary from Nanette F. Santoro, MD, Professor and Director, Division of Reproductive Endocrinology, Department of Ob/Gyn and Women's Health, Albert Einstein College of Medicine, Bronx, NY.

This very interesting trial clearly demonstrates marked subjective improvement in vasomotor symptoms compared with placebo at a surprisingly low dose of estradiol. The 41% 'responder' rate suggests that many women may find significant relief of their hot flushes at hormone doses previously considered homeopathic.

Related Videos
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Enhancing cervical cancer management with dual stain | Image Credit: linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
Understanding the impact of STIs on young adults | Image Credit: providers.ucsd.edu.
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Related Content
© 2024 MJH Life Sciences

All rights reserved.